Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-Drug dependence is not physical dependence alone, nor is it the same as drug tolerance. "Drug dependence is primarily psychological dependence, or compulsive use of drugs for their mood-altering effects and continued use despite harm," David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

VANCOUVER, BC-Drug dependence is not physical dependence alone,nor is it the same as drug tolerance. "Drug dependence isprimarily psychological dependence, or compulsive use of drugsfor their mood-altering effects and continued use despite harm,"David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

The WHO Expert Committee on Drug Dependence recently clarifiedthat a cancer patient who has been receiving opioids for painand who stops the drug would go through a withdrawal syndromeas evidence of physical dependence, but that individual is notconsidered to be drug dependent.

"Physical dependence by itself is no longer sufficient todefine drug dependence or addiction," Mr. Joranson said."It is important for us to teach this and to clear up themythology about the relationship between opioid analgesia andaddiction."

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Related Content